Approval · Notice of Compliance 28509 · 2022
MS CONTIN: Notice of Compliance 28509
Issued July 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28509
- Date
- July 4, 2022
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM) and Conversion to the 2020 Master PM template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MS CONTIN | Not yet assigned | — |
Medicinal ingredients
- MORPHINE SULFATE 15 MG per TAB
- MORPHINE SULFATE 30 MG per TAB
- MORPHINE SULFATE 60 MG per TAB
- MORPHINE SULFATE 100 MG per TAB
- MORPHINE SULFATE 200 MG per TAB